| Penicillin binding protein 2a: An overview and a medicinal chemistry perspective MAW Shalaby, EME Dokla, RAT Serya, KAM Abouzid European journal of medicinal chemistry 199, 112312, 2020 | 84 | 2020 |
| Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria EME Dokla, NS Abutaleb, SN Milik, D Li, K El-Baz, MAW Shalaby, ... European Journal of Medicinal Chemistry 186, 111850, 2020 | 53 | 2020 |
| 1, 2, 4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC EME Dokla, CS Fang, KAM Abouzid, CS Chen European Journal of Medicinal Chemistry 182, 111607, 2019 | 30 | 2019 |
| SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria EME Dokla, NS Abutaleb, SN Milik, EAEA Kandil, OM Qassem, ... European Journal of Medicinal Chemistry 247, 115040, 2023 | 10 | 2023 |
| Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia EME Dokla, AK Abdel-Aziz, SN Milik, MJ McPhillie, S Minucci, ... Bioorganic & Medicinal Chemistry 56, 116596, 2022 | 10 | 2022 |
| Applying ligands profiling using multiple extended electron distribution based field templates and feature trees similarity searching in the discovery of new generation of urea … EM Dokla, AH Mahmoud, MSA Elsayed, AH El-Khatib, MW Linscheid, ... Plos one 7 (11), e49284, 2012 | 10 | 2012 |
| A 5′ AMP‐activated protein kinase enzyme activator, compound 59, induces autophagy and apoptosis in human oral squamous cell carcinoma JR Weng, EME Dokla, LY Bai, CS Chen, SJ Chiu, TM Shieh Basic & Clinical Pharmacology & Toxicology 123 (1), 21-29, 2018 | 9 | 2018 |
| Targeting YAP degradation by a novel 1, 2, 4-oxadiazole derivative via restoration of the function of the Hippo pathway EME Dokla, CS Fang, PC Chu, CS Chang, KAM Abouzid, CS Chen ACS Medicinal Chemistry Letters 11 (4), 426-432, 2020 | 7 | 2020 |
| Identification of novel pyrazole and benzimidazole based derivatives as PBP2a inhibitors: Design, synthesis, and biological evaluation MAW Shalaby, EME Dokla, RAT Serya, KAM Abouzid Archives of Pharmaceutical Sciences Ain Shams University 3 (2), 228-245, 2019 | 7 | 2019 |
| Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer EME Dokla, AK Abdel-Aziz, SN Milik, AH Mahmoud, MK Saadeldin, ... Bioorganic Chemistry 117, 105451, 2021 | 6 | 2021 |
| Discovery of EMD37, a 1, 2, 4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity AK Abdel-Aziz, EME Dokla, KAM Abouzid, S Minucci Biochemical Pharmacology 206, 115316, 2022 | 5 | 2022 |
| Development of potent adenosine monophosphate activated protein kinase (AMPK) activators EME Dokla, CS Fang, PT Lai, SK Kulp, RAT Serya, NSM Ismail, ... ChemMedChem 10 (11), 1915-1923, 2015 | 4 | 2015 |
| FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: an updated comprehensive review AK Abdel-Aziz, EME Dokla, MK Saadeldin Critical Reviews in Oncology/Hematology, 104139, 2023 | 3 | 2023 |
| Induction of apoptosis using ATN as a novel Yes‐associated protein inhibitor in human oral squamous cell carcinoma cells PC Chu, EME Dokla, JL Hu, JR Weng Environmental Toxicology 37 (6), 1404-1412, 2022 | 3 | 2022 |
| Ligand design, synthesis and biological anti-HCV evaluations for genotypes 1b and 4a of certain 4-(3-& 4-[3-(3, 5-dibromo-4-hydroxyphenyl)-propylamino] phenyl) butyric acids … MAH Ismail, KAM Abouzid, NS Mohamed, EME Dokla Journal of Enzyme Inhibition and Medicinal Chemistry 28 (6), 1274-1290, 2013 | 3 | 2013 |
| Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells SWA Helmy, AK Abdel-Aziz, EME Dokla, TE Ahmed, Y Hatem, ... European Journal of Medicinal Chemistry, 116255, 2024 | | 2024 |
| Nanoemulgel formulation of a benzimidazole derivative for wound healing EME Dokla, RI El-Gogary, NM Abd-Elsaid, M Gad, RK Abd-Elhalim, ... Journal of Drug Delivery Science and Technology 90, 105121, 2023 | | 2023 |
| AML and FLT3: An update on FDA-approved or under review kinase inhibitors targeting FLT3 kinase N Alaa El-Deen, EME Dokla, MY Jaballah, K Abouzid, RA Serya Egyptian Journal of Chemistry, 2023 | | 2023 |
Khaled Abouzidprofessor of pharmaceutical chemistryVerified email at pharma.asu.edu.eg
